Key points are not available for this paper at this time.
To compare the efficacy of subcutaneous foslevodopa/foscarbidopa (LDP/CDP) with oral levodopa/carbidopa (LD/CD) across prespecified subgroups of patients with advanced Parkinson's disease (PD) in a phase 3 study.
Kern et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: